enVVeno Medical Corporation provided an update on enrollment for its ongoing SAVVE (Surgical Anti-reflux Venous Valve Endoprosthesis) U.S. pivotal study for the VenoValve and announced two upcoming investor events. The SAVVE pivotal study is a prospective, non-blinded, single arm, multi-center study of 75 CVI patients. To date, the Company has enrolled 57 patients in the study and expects enrollment to be completed before the end of 2023.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.96 USD | -1.00% | +1.02% | -3.50% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-3.50% | 66.12M | |
+54.05% | 58.71B | |
-2.02% | 41.31B | |
+37.04% | 39.2B | |
-10.22% | 27.4B | |
+13.42% | 26.55B | |
-21.60% | 18.98B | |
+2.89% | 12.51B | |
+27.49% | 12.08B | |
+22.40% | 11.94B |
- Stock Market
- Equities
- NVNO Stock
- News enVVeno Medical Corporation
- Envveno Medical Corporation Provides Enrollment Update for Ongoing VenoValve(R) U.S. Pivotal Study